Principles of Tumor Suppression

Cell

Volumn 116, Issue 2, 2004, Pages 235-246

  Sherr, Charles J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CHECKPOINT KINASE 2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PROTEIN P53; RAS PROTEIN; SMAD4 PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; VON HIPPEL LINDAU PROTEIN; WNT PROTEIN; WT1 PROTEIN;

ANGIOGENESIS; AUTOSOMAL DOMINANT INHERITANCE; CANCER INHIBITION; CANCER RESEARCH; CARCINOGENESIS; CELL ACTIVITY; CELL CYCLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL SPECIFICITY; DNA DAMAGE; DNA REPAIR; FAMILIAL CANCER; GENE FUNCTION; HUMAN; MITOSIS; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECESSIVE INHERITANCE; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

ANIMALIA; ERINACEIDAE;

EID: 0842346437     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(03)01075-4     Document Type: Review

References (105)

1. Artandi S.E., Chang S., Lee S.L., Alson S., Gottlieb G.J., Chin L., DePinho R.A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature. 406:2000;573-574.
2. Baker S.J., Markowitz S., Fearon E.R., Willson J.K.V., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 249:1990;912-915.
3. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 421:2003;499-506.
4. Balmain A., Nagase H. Cancer resistance genes in mice. models for the study of tumour modifiers Trends Genet. 14:1998;139-144.
5. Balmain A., Gray J., Ponder B. The genetics and genomics of cancer. Nat. Genet. 33:2003;238-244.
6. Bell D., Varley J.M., Zydlo T.E., Kang D.H., Wahrer D.C., Shannon K.E., Lubratovitch M., Verselis S.J., Isselbacher K.J., Fraumeni J.F.et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 286:1999;2528-2531.
7. Benedict W.F., Murphree A.L., Banerjee A., Spina C.A., Sparkes M.C., Sparkes R.S. Patient with 13 chromosome deletion. evidence that the retinoblastoma gene is a recessive cancer gene Science. 219:1983;973-975.
8. nd Edition:1985;249-356 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
9. Blain S.W., Scher H.I., Cordon-Cardo C., Koff A. p27 as a target for cancer therapeutics. Cancer Cell. 3:2003;111-115.
10. Cahill D.P., Lengauer C., Yu J., Riggins G.J., Willson J.K.V., Markowitz S.D., Kinzler K.W., Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature. 392:1998;300-303.
11. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2002;1655-1657.
12. Cavenee W.K., Dryja T.P., Phillips R.A., Benedict W.F., Godbout R., Gallie B.L., Murphree A.L., Strong L.C., White R.L. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 305:1983;779-784.
13. Chung D.C., Rustgi A.K. The hereditary nonpolyposis colorectal cancer syndrome. genetics and clinical implications Ann. Intern. Med. 138:2003;560-570.
14. Comings D.E. A general theory of carcinogenesis. Proc. Natl. Acad. Sci. USA. 70:1973;3324-3328.
15. Cook W.D., McCaw B.J. Accommodating haploinsufficient tumour suppressor genes in Knudson's model. Oncogene. 19:2000;3434-3438.
16. D'Andrea A.D., Grompe M. The Fanconi Anaemia/BRCA pathway. Nat. Rev. Cancer. 3:2003;23-34.
17. Eliyahu D., Raz A., Gruss P., Givol D., Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature. 312:1984;646-649.
18. Eliyahu D., Goldfinger N., Pinhasi-Kimhi O., Shaulsky G., Skurnick Y., Ara N., Rotter V., Oren M. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene. 3:1988;313-321.
19. Elledge S.J., Amon A. The BRCA1 suppressor hypothesis. an explanation for the tissue-specific tumor development in BRCA1 patients Cancer Cell. 1:2002;129-132.
20. Fearnhead N.S., Britton M.P., Bodmer W.F. The ABC of APC. Hum. Mol. Genet. 10:2001;721-733.
21. Kip1 is haplo-insufficient for tumour suppression. Nature. 396:1998;177-180.
22. Finlay C.A., Hinds P.W., Tan T.H., Eliyahu D., Oren M., Levine A.J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 8:1988;531-539.
23. Finlay C.A., Hinds P.W., Levine A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 57:1989;1083-1093.
24. Fishel R., Lescoe M.K., Rao M.R.S., Copeland N.G., Jenkins N.A., Garber J., Kane M., Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 75:1993;1027-1038.
25. Francke U., Kung F. Sporadic bilateral retinoblastoma and 13q-deletion. Med. Pediatr. Oncol. 2:1976;379-385.
26. Friend S.H., Bernards R., Rogelj S., Weinberg R.A., Rapaport J.M., Albert D.M., Dryja T.P. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 323:1986;643-646.
27. Gorlin R.J. Nevoid basal-cell carcinoma syndrome. Medicine. 66:1987;98-113.
28. Gottardi C.J., Wong E., Gumbiner B.M. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J. Cell Biol. 153:2001;1049-1060.
29. Grady W.M., Myeroff L.L., Swinler S.E., Rajput A., Thiagalingam S., Lutterbaugh J.D., Neumann A., Brattain M.G., Chang J., Kim S.J.et al. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res. 59:1999;320-324.
30. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H., Joslyn G., Stevens J., Spirio L., Robertson M.et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 66:1991;589-600.
31. Hahn H., Wicking C., Zaphiropoulous P.G., Gailani M.R., Shanley S., Chidambaram A., Vorechovsky I., Holmberg E., Unden A.B., Gillies S.et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 85:1996;841-851. a.
32. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:1996;350-353. b.
33. Hanahan D., Folkman J. Patterns and emerging machanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
34. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
35. Harbour J.W., Dean D.C. The Rb/E2F pathway. expanding roles and emerging paradigms Genes Dev. 14:2000;2393-2409.
36. Harris H., Miller O.J., Klein G., Worst P., Tachibana T. Suppression of malignancy by cell fusion. Nature. 223:1969;363-368.
37. Hinds P.W., Finlay C.A., Frey A.B., Levine A.J. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol. Cell. Biol. 7:1987;2863-2869.
38. Hinds P., Finlay C., Levine A.J. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. 63:1989;739-746.
39. Howe J.R., Roth S., Ringold J.C., Summers R.W., Jarvinen H.J., Sistonen P., Tomlinson I.P., Houlston R.S., Bevan S., Mitros F.A.et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 280:1998;1086-1088.
40. Ionov Y., Peinado M.A., Malkhosyan S., Shibata D., Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveals a new mechanism for colonic carcinogenesis. Nature. 363:1993;558-561.
41. Jasin M. Homologous repair of DNA damage and tumorigenesis. the BRCA connection Oncogene. 21:2002;8981-8993.
42. Johnson R.L., Rothman A.L., Xie J., Goodrich L.V., Bare J.W., Bonifas J.M., Quinn A.G., Myers R.M., Cox D.R., Epstein E.H., Scott M.P. Human homolog of patched, a candidate gene for basal cell nevus syndrome. Science. 272:1996;1668-1671.
43. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2:2002;673-682.
44. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day R.S. III, Johnson B.E., Skolnick M.H. A cell cycle regulator involved in genesis of many tumor types. Science. 264:1994;436-440.
45. ARF. Cell. 91:1997;649-659.
46. Kastan M.B., Lim D.-S. The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 1:2000;179-186.
47. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
48. Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA binding protein. Science. 252:1991;1708-1711.
49. Kinzler K.W., Nilbert M.C., Su L.K., Vogelstein B., Bryan T.M., Levy D.B., Smith K.J., Preisinger A.C., Hedge P., McKechnie D.et al. Identification of FAP locus genes from chromosome 5q21. Science. 253:1991;661-665.
50. Knudson A.G. Mutation and cancer. statistical study of retinoblastoma Proc. Natl. Acad. Sci. USA. 68:1971;820-823.
51. Knudson A.G. Mutation and human cancer. Adv. Cancer Res. 17:1973;317-352.
52. Knudson A.G., Meadows A.T., Nichols W.W., Hill R. Chromosomal deletion and retinoblastoma. N. Engl. J. Med. 295:1976;1120-1123.
53. -/- colon carcinoma. Science. 275:1997;1784-1787.
54. Korinek V., Barker N., Moerer P., van Donselaar E., Huls G., Peters P.J., Clevers H. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat. Genet. 19:1998;379-383.
55. Ink4a confers susceptibility to metastatic melanoma in mice. Nature. 413:2001;83-86.
56. Lane D.P., Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature. 278:1979;261-263.
57. Lanni J.S., Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18:1998;1055-1064.
58. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
59. Linzer D.I., Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 17:1979;43-52.
60. Loeb L.A., Loeb K.R., Anderson J.P. Multiple mutations and cancer. Proc. Natl. Acad. Sci. USA. 100:2003;776-781.
61. Maehama T., Dixon J.E. Pten. a tumour suppressor that functions as a phospholipid phosphatase Trends Cell Biol. 9:1999;125-128.
62. Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., Kass J., Gryka M.A., Bischoff F.Z., Tainsky M.A.et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1990;1233-1238.
63. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science. 275:1997;1787-1790.
64. Mowat M., Cheng A., Kimura N., Bernstein A., Benchimol S. Rearrangements of the cellular p53 gene in erythroleukemic cells transformed by Friend virus. Nature. 314:1985;633-636.
65. Murone M., Rosenthal A., de Sauvage F.J. Hedgehog signal transduction. from flies to vertebrates Exp. Cell Res. 253:1999;25-33.
66. Nevins J.R. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 10:2001;699-703.
67. Nigg E.A. Centrosome aberrations. cause or consequence of cancer progression Nat. Rev. Cancer. 2:2002;815-825.
68. Noel B., Quack B., Rethore M.O. Partial deletions and trisomies of chromosome 13. mapping of bands associated with particular malformations Clin. Genet. 9:1976;593-602.
69. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database. new online mutation analysis and recommendations to users Hum. Mutat. 19:2002;607-614.
70. Oren M., Levine A.J. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc. Natl. Acad. Sci. USA. 80:1983;56-59.
71. Parada L.F., Land H., Weinberg R.A., Wolf D., Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature. 312:1984;649-651.
72. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim. Biophys. Acta. 1332:1997;F127-F147.
73. Powell S.M., Zilz N., Beazer-Barclay Y., Bryan T.M., Hamilton S.R., Thibodeau S.N., Vogelstein B., Kinzler K.W. APC mutations occur early during colorectal tumorigenesis. Nature. 359:1992;235-237.
74. Prives C. Signaling to p53. breaking the MDM2-p53 circuit Cell. 95:1998;5-8.
75. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000.
76. Quon K.C., Berns A. Haplo-insufficiency? Let me count the ways. Genes Dev. 15:2001;2917-2921.
77. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature. 414:2001;105-111.
78. Rosen E.M., Fan S., Pestell R.G., Goldberg I.D. BRCA1 gene in breast cancer. J. Cell. Physiol. 196:2003;19-41.
79. INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta. 1378:1998;F115-F177.
80. Rubinfeld B., Souza B., Albert I., Muller O., Chamberlain S.H., Masiarz F.R., Munemitsu S., Polakis P. Association of the APC gene product with beta-catenin. Science. 262:1993;1731-1734.
81. Schutte M., Hruban R.H., Hedrick L., Cho K.R., Nadasdy G.M., Weinstein C.L., Bova G.S., Isaacs W.B., Cairns P., Nawroz H.et al. DPC4 gene in various tumor types. Cancer Res. 56:1996;2527-2530.
82. Scully R., Livingston D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 408:2000;429-432.
83. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15:1999;551-578.
84. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
85. Serrano M., Lee H.-W., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 85:1996;27-37.
86. INK4a. Cell. 88:1997;593-602.
87. Sharpless N.E., DePinho R.A. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9:1999;22-30.
88. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2:2001;731-737.
89. Shi Y., Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 113:2003;685-700.
90. Shih I.M., Yu J., He T.C., Vogelstein B., Kinzler K.W. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res. 60:2000;1671-1676.
91. Shiloh Y., Kastan M.B. Atm. genome stability, neuronal development, and cancer cross paths Adv. Cancer Res. 83:2001;209-254.
92. Siegel P.M., Massagué J. TGF-β cytostatic and apoptotic programs in homeostasis and cancer. Nat. Rev. Cancer. 11:2003;807-821.
93. Stanbridge E.J. Suppression of malignancy in human cells. Nature. 260:1976;17-20.
94. Stehelin D., Varmus H.E., Bishop J.M., Vogt P.K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 260:1976;170-173.
95. Stocker H., Andjelkovic M., Oldham S., Laffargue M., Wymann M.P., Hemmings B.A., Hafen E. Living with lethal PIP3 levels. viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB Science. 295:2002;2088-2091.
96. Su L.K., Vogelstein B., Kinzler K.W. Association of the APC tumor suppressor protein with catenins. Science. 262:1993;1734-1737.
97. Sulis M.L., Parsons R. Pten. from pathology to biology Trends Cell Biol. 13:2003;478-483.
98. Taipale J., Beachy P.A. The hedgehog and Wnt signalling pathways in cancer. Nature. 411:2001;349-354.
99. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., Blenis J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13:2003;1259-1268.
100. Trimarchi J.M., Lees J.A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 3:2002;11-20.
101. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T.et al. Pten dose dictates cancer progression in the prostate. PLoS Biology. 1:2003;385-396.
102. Venkatachalam S., Shi Y.P., Jones S.N., Vogel H., Bradley A., Pinkel D., Donehower L.A. Retention of wild-type p53 in tumors from p53 heterozygous mice. reduction of p53 dosage can promote cancer formation EMBO J. 17:1998;4657-4667.
103. Wechsler-Reya R.J., Scott M.P. Control of neuronal precursor proliferation in the cerebellum by Sonic hedgehog. Neuron. 22:2003;103-114.
104. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
105. Weissman I.L. Stem cells. units of development, units of regeneration, and units in evolution Cell. 100:2000;157-168.